Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CNBC's Angelica Peebles reports on news regarding CVS. Qantas hit by cyberattack, six million customers' data potentially ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

About 69,000 new cases and nearly 14,000 deaths are expected this year, according to the American Cancer Society.

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...